Online Management of Breast Diseases Patient Education |  Physician Guidelines |  Treatment Index
News |  TransMed |  E-Mail |  Disclaimer

Onc.Protocol:Clas.CMF STAGE IV




Classical CMF-STAGE IV

Cyclophosphamide & Methotrexate & 5-Florouracil

IDENTIFICATION: Combination chemotherapy with cyclophosphamide (Cytoxan), methotrexate and florouracil (5FU); also called "Classical CMF".
These drugs have been approved by the FDA (Food and Drug Administration) for the treatment of breast cancer.
DOSES: Cyclophosphamide 100 mg/M2, Methotrexate 40 mg/M2, Florouracil 600 mg/M2
ROUTE: Intravenous (IV) methotrexate and 5FU. Oral cytoxan
DURATION AND TIMING: Cytoxan is given for 14 days in a row orally; methotrexate and 5FU are given the first day and repeated one week later. The treatments are repeated every 28 days. Treatments are generally continued if the drug keeps the breast cancer from growing unless there are unacceptable side effects.
Possible Side effects:
  • Hematopoetic: decrease in blood cells, especially white cells (neutropenia) but also red cells (anemia) and/or platelets (thrombocytopenia).
  • Gastrointestinal: possible nausea and vomiting (which may be decreased or prevented with medications); diarrhea; mouth sores; decreased appetite.
  • Integmentary: moderate to severe hair loss; dry skin, nail thinning or ridging.
  • Genitourinary: cytoxan may cause irritation to the kidneys or bladder.
  • Fertility: cytoxan may cause damage to the ovaries of premenopausal women. This may lead to temporary or permanent infertility. Patients may also develop an early menopause.
  • Cardiovascular: rare instances of irregular heart beats or chest discomfort have been attributed to 5FU (risk is increased in those with underlying heart disease).
  • Neurological: some patients complain of a decrease in their ability to concentrate and/or remember, which improves on completion of therapy.
  • Other: some patients complain of taste changes and/or lack of appetite.

Back gif


1997 - TransMed Network